SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $301,290 | -30.7% | 20,750 | -0.0% | 0.01% | -31.2% |
| Q2 2023 | $434,507 | -11.5% | 20,760 | -10.7% | 0.02% | 0.0% |
| Q1 2023 | $491,040 | -25.6% | 23,250 | -10.4% | 0.02% | -33.3% |
| Q4 2022 | $660,173 | +7.2% | 25,940 | +1.2% | 0.02% | +4.3% |
| Q3 2022 | $616,000 | +34.2% | 25,640 | +7.6% | 0.02% | +43.8% |
| Q2 2022 | $459,000 | +7.5% | 23,840 | -3.1% | 0.02% | +23.1% |
| Q1 2022 | $427,000 | -20.6% | 24,590 | 0.0% | 0.01% | -13.3% |
| Q4 2021 | $538,000 | +13.5% | 24,590 | -0.8% | 0.02% | +7.1% |
| Q3 2021 | $474,000 | +9.5% | 24,790 | -1.8% | 0.01% | +7.7% |
| Q2 2021 | $433,000 | -23.9% | 25,240 | -0.8% | 0.01% | -27.8% |
| Q1 2021 | $569,000 | +0.2% | 25,440 | -0.3% | 0.02% | -5.3% |
| Q4 2020 | $568,000 | +47.2% | 25,525 | -2.3% | 0.02% | +26.7% |
| Q3 2020 | $386,000 | 0.0% | 26,125 | +0.4% | 0.02% | -11.8% |
| Q2 2020 | $386,000 | +238.6% | 26,025 | +111.9% | 0.02% | +183.3% |
| Q2 2019 | $114,000 | – | 12,280 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |